Elanco Animal Health Files 8-K on Exit Costs

TL;DR

Elanco 8-K filed: Exit/disposal costs and Reg FD disclosures as of Dec 5, 2025.

AI Summary

Elanco Animal Health Incorporated filed an 8-K on December 9, 2025, reporting on cost associated with exit or disposal activities and Regulation FD disclosures as of December 5, 2025. The filing details financial statements and exhibits related to these activities.

Why It Matters

This filing indicates Elanco is undergoing restructuring or divesting certain assets, which could impact its future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Disposal activities can signal financial strain or strategic shifts that may carry inherent risks.

Key Players & Entities

• Elanco Animal Health Incorporated (company) — Registrant
• December 5, 2025 (date) — Date of Earliest Event Reported
• December 9, 2025 (date) — Filing Date
• 450 Elanco Circle Indianapolis, Indiana 46221 (address) — Principal executive offices

FAQ

Key Financial Figures

• $175 m — Restructuring Plan total approximately $175 million, the majority of which will be in
• $130 million — ncurred in 2025, including an estimated $130 million of cash-based costs, most of which is e
• $45 million — d in the next 2 years, and an estimated $45 million of non-cash asset impairment charges pr

Filing Documents

• tm2533048d1_8k.htm (8-K) — 31KB
• tm2533048d1_ex99-1.htm (EX-99.1) — 56KB
• tm2533048d1_ex99-1img001.jpg (GRAPHIC) — 14KB
• 0001104659-25-119486.txt ( ) — 320KB
• elan-20251205.xsd (EX-101.SCH) — 3KB
• elan-20251205_def.xml (EX-101.DEF) — 26KB
• elan-20251205_lab.xml (EX-101.LAB) — 35KB
• elan-20251205_pre.xml (EX-101.PRE) — 25KB
• tm2533048d1_8k_htm.xml (XML) — 4KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On December 5, 2025, the Board of Directors of Elanco Animal Health Incorporated (the "Company") authorized a restructuring plan with respect to its workforce (the "Restructuring Plan") to support margin expansion, optimize the Company's footprint, and further invest in innovation. The Restructuring Plan will result in a global headcount reduction of approximately 300 employees, plus an approximate 300 employees whose positions will be replaced with positions in growth areas or in lower-cost geographies. Expected pretax charges associated with the Restructuring Plan total approximately $175 million, the majority of which will be incurred in 2025, including an estimated $130 million of cash-based costs, most of which is expected to be paid in the next 2 years, and an estimated $45 million of non-cash asset impairment charges primarily related to the Company's closure of its Kansas City, Missouri implant facility and exit from a portion of its Monheim, Germany facility.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 9, 2025, the Company issued a press release in connection with its 2025 Investor Day announcing the Company's innovation and financial outlook, including reaffirming its fourth quarter and full year 2025 guidance, and describing other matters including the Restructuring Plan. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Elanco Animal Health Incorporated, dated as of December 9, 2025. 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elanco Animal Health Incorporated Date: December 9, 2025 By: /s/ Robert M. VanHimbergen Name: Robert M. VanHimbergen Title: Executive Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR